US 12,326,441 B2
Method and apparatus for providing data processing and control in a medical communication system
Gary Alan Hayter, Oakland, CA (US); Geoffrey V. McGarraugh, San Rafael, CA (US); Andrew H. Naegeli, Walnut Creek, CA (US); John Charles Mazza, Long Beach, CA (US); and Benjamin Jay Feldman, Berkeley, CA (US)
Assigned to ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed by ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed on Oct. 24, 2023, as Appl. No. 18/493,731.
Application 18/493,731 is a continuation of application No. 17/735,591, filed on May 3, 2022, granted, now 11,828,748.
Application 17/735,591 is a continuation of application No. 17/717,556, filed on Apr. 11, 2022.
Application 17/717,556 is a continuation of application No. 17/473,692, filed on Sep. 13, 2021, granted, now 11,300,561, issued on Apr. 12, 2022.
Application 17/473,692 is a continuation of application No. 17/228,531, filed on Apr. 12, 2021, granted, now 11,119,090, issued on Sep. 14, 2021.
Application 17/228,531 is a continuation of application No. 17/102,229, filed on Nov. 23, 2020, granted, now 10,976,304, issued on Apr. 13, 2021.
Application 17/102,229 is a continuation of application No. 16/824,568, filed on Mar. 19, 2020, abandoned.
Application 16/824,568 is a continuation of application No. 16/181,069, filed on Nov. 5, 2018, granted, now 10,634,662, issued on Apr. 28, 2020.
Application 16/181,069 is a continuation of application No. 15/796,274, filed on Oct. 27, 2017, granted, now 10,119,956, issued on Nov. 6, 2018.
Application 15/796,274 is a continuation of application No. 14/223,893, filed on Mar. 24, 2014, granted, now 9,804,150, issued on Oct. 31, 2017.
Application 14/223,893 is a continuation of application No. 13/567,038, filed on Aug. 4, 2012, granted, now 8,682,615, issued on Mar. 25, 2014.
Application 13/567,038 is a continuation of application No. 12/152,652, filed on May 14, 2008, granted, now 8,239,166, issued on Aug. 7, 2012.
Claims priority of provisional application 60/917,837, filed on May 14, 2007.
Prior Publication US 2024/0069009 A1, Feb. 29, 2024
Int. Cl. G01N 33/49 (2006.01); A61B 5/145 (2006.01); A61B 5/1473 (2006.01); A61B 5/1495 (2006.01); G16H 10/40 (2018.01); G16H 15/00 (2018.01); G16H 20/10 (2018.01); G16H 40/40 (2018.01); G16H 40/67 (2018.01); G16H 50/50 (2018.01)
CPC G01N 33/49 (2013.01) [A61B 5/14532 (2013.01); A61B 5/1473 (2013.01); A61B 5/1495 (2013.01); G16H 10/40 (2018.01); G16H 20/10 (2018.01); G16H 40/67 (2018.01); A61B 2560/0223 (2013.01); A61B 2560/0252 (2013.01); G16H 15/00 (2018.01); G16H 40/40 (2018.01); G16H 50/50 (2018.01)] 11 Claims
OG exemplary drawing
 
1. A glucose monitoring system, comprising:
a glucose sensor including
a first portion configured to be positioned above a skin layer of the user, and
a second portion configured to be implanted transcutaneously below the skin layer of the user into a subcutaneous space and in contact with an interstitial fluid of the user and having
a working electrode, and
a reference electrode,
wherein the glucose sensor is configured to generate data signals associated with a glucose level of the interstitial fluid;
one or more processors; and
one or more memories storing a sensor code from manufacturing, wherein the memories are operatively coupled to the one or more processors for storing instructions which, when executed by the one or more processors, cause the one or more processors to:
retrieve a sensitivity and a predefined sensitivity range from the sensor code from manufacturing;
receive an unscheduled manual user calibration;
determine a composite sensitivity using a time based function based on the sensitivity, the predefined sensitivity range, and the unscheduled manual user calibration; and
determine a glucose level of the user based on the composite sensitivity and the data signals generated by the glucose sensor.